Bifogade filer
Kurs
+0,35%
Likviditet
40,0 MDKK
Kalender
| Est. tid* | ||
| 2026-12-02 | N/A | Årsstämma |
| 2026-11-05 | 08:00 | Bokslutskommuniké 2026 |
| 2026-08-26 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-05-06 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-02-04 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2025-12-04 | - | X-dag ordinarie utdelning AMBU B 0.41 DKK |
| 2025-12-03 | - | Årsstämma |
| 2025-11-05 | - | Bokslutskommuniké 2025 |
| 2025-08-22 | - | Kvartalsrapport 2025-Q3 |
| 2025-05-07 | - | Kvartalsrapport 2025-Q2 |
| 2025-01-30 | - | Kvartalsrapport 2025-Q1 |
| 2024-12-05 | - | X-dag ordinarie utdelning AMBU B 0.38 DKK |
| 2024-12-04 | - | Årsstämma |
| 2024-11-05 | - | Bokslutskommuniké 2024 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-14 | - | Kvartalsrapport 2024-Q2 |
| 2024-01-30 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-14 | - | X-dag ordinarie utdelning AMBU B 0.00 DKK |
| 2023-12-13 | - | Årsstämma |
| 2023-11-08 | - | Bokslutskommuniké 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q3 |
| 2023-05-03 | - | Kvartalsrapport 2023-Q2 |
| 2023-02-07 | - | Kvartalsrapport 2023-Q1 |
| 2022-12-15 | - | X-dag ordinarie utdelning AMBU B 0.00 DKK |
| 2022-12-14 | - | Årsstämma |
| 2022-11-15 | - | Bokslutskommuniké 2022 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-05-10 | - | Kvartalsrapport 2022-Q2 |
| 2022-02-08 | - | Kvartalsrapport 2022-Q1 |
| 2021-12-15 | - | X-dag ordinarie utdelning AMBU B 0.29 DKK |
| 2021-12-14 | - | Årsstämma |
| 2021-11-09 | - | Bokslutskommuniké 2021 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q2 |
| 2021-01-27 | - | Kvartalsrapport 2021-Q1 |
| 2020-12-10 | - | X-dag ordinarie utdelning AMBU B 0.29 DKK |
| 2020-12-09 | - | Årsstämma |
| 2020-11-11 | - | Bokslutskommuniké 2020 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-05-05 | - | Kvartalsrapport 2020-Q2 |
| 2020-02-04 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-18 | - | X-dag ordinarie utdelning AMBU B 0.38 DKK |
| 2019-12-17 | - | Årsstämma |
| 2019-11-13 | - | Bokslutskommuniké 2019 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-05-01 | - | Kvartalsrapport 2019-Q2 |
| 2019-01-31 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-13 | - | X-dag ordinarie utdelning AMBU B 0.40 DKK |
| 2018-12-12 | - | Årsstämma |
| 2018-11-13 | - | Bokslutskommuniké 2018 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-05-07 | - | Kvartalsrapport 2018-Q2 |
| 2018-01-31 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-03 | - | Split AMBU B 1:5 |
| 2017-12-14 | - | X-dag ordinarie utdelning AMBU B 1.85 DKK |
| 2017-12-13 | - | Årsstämma |
| 2017-09-30 | - | Bokslutskommuniké 2017 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-05-02 | - | Kvartalsrapport 2017-Q2 |
| 2017-02-01 | - | Kvartalsrapport 2017-Q1 |
| 2016-12-13 | - | X-dag ordinarie utdelning AMBU B 1.55 DKK |
| 2016-12-12 | - | Årsstämma |
| 2016-09-30 | - | Bokslutskommuniké 2016 |
| 2016-08-19 | - | Kvartalsrapport 2016-Q3 |
| 2016-05-03 | - | Kvartalsrapport 2016-Q2 |
| 2016-01-29 | - | Kvartalsrapport 2016-Q1 |
| 2015-12-11 | - | X-dag ordinarie utdelning AMBU B 0.95 DKK |
| 2015-12-10 | - | Årsstämma |
| 2015-11-11 | - | Bokslutskommuniké 2015 |
| 2015-08-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-05-06 | - | Kvartalsrapport 2015-Q2 |
| 2015-02-02 | - | Kvartalsrapport 2015-Q1 |
| 2014-12-23 | - | Split AMBU B 1:4 |
| 2014-12-18 | - | X-dag ordinarie utdelning AMBU B 3.75 DKK |
| 2014-12-17 | - | Årsstämma |
| 2014-11-13 | - | Bokslutskommuniké 2014 |
| 2014-08-20 | - | Kvartalsrapport 2014-Q3 |
| 2014-05-02 | - | Kvartalsrapport 2014-Q2 |
| 2014-02-04 | - | Kvartalsrapport 2014-Q1 |
| 2013-12-13 | - | X-dag ordinarie utdelning AMBU B 1.25 DKK |
| 2013-12-12 | - | Årsstämma |
| 2013-09-30 | - | Bokslutskommuniké 2013 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q3 |
| 2013-05-02 | - | Kvartalsrapport 2013-Q2 |
| 2013-02-05 | - | Kvartalsrapport 2013-Q1 |
| 2012-12-14 | - | X-dag ordinarie utdelning AMBU B 3.00 DKK |
| 2012-12-13 | - | Årsstämma |
| 2012-09-30 | - | Bokslutskommuniké 2012 |
| 2012-08-23 | - | Kvartalsrapport 2012-Q3 |
| 2012-05-03 | - | Kvartalsrapport 2012-Q2 |
| 2012-02-09 | - | Kvartalsrapport 2012-Q1 |
| 2011-12-16 | - | X-dag ordinarie utdelning AMBU B 2.00 DKK |
| 2011-12-15 | - | Årsstämma |
| 2011-09-30 | - | Bokslutskommuniké 2011 |
| 2011-08-25 | - | Kvartalsrapport 2011-Q3 |
| 2011-05-09 | - | Kvartalsrapport 2011-Q2 |
| 2011-02-07 | - | Kvartalsrapport 2011-Q1 |
| 2010-12-17 | - | X-dag ordinarie utdelning AMBU B 2.50 DKK |
| 2009-12-17 | - | X-dag ordinarie utdelning AMBU B 1.50 DKK |
| 2005-03-01 | - | Split AMBU B 1:2 |
| 2004-02-10 | - | Split AMBU B 1:10 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
10.12.2025 08:00:00 CET | Ambu A/S | Changes in company's own shares
Ambu A/S is initiating a new share buyback program under which Ambu will repurchase shares for a total amount of up to DKK 150m from 10 December 2025 until no later than 31 March 2026.
The share buyback program is being launched within the authority granted by the shareholders at the annual general meeting held on 14 December 2022, for the repurchase of up to 10% of the company’s share capital, provided that the purchase price does not deviate by more than 10% from the most recently quoted market price for the company’s B-shares at the time of the acquisition. Prior to the launch of the share buyback program, Ambu holds 2,738,985 treasury shares, equal to 1.0% of the company’s share capital.
The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations, with the purpose of completing a share capital decrease as set out in Article 5(2)(a) in MAR.
Ambu has retained BNP PARIBAS to act as lead manager of the share buyback program and purchase shares on behalf of Ambu. BNP PARIBAS has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company.
Ambu will be entitled to suspend the share buyback program at any time. Should the share buyback program be suspended, Ambu will announce this in a company announcement, and the manager will stop buying back shares in the market. The repurchased shares are bought with the aim of future cancellation.
Terms of the share buyback program
Under the share buyback program, Ambu may repurchase shares up to a maximum amount of DKK 150m, and no more than 3,000,000 shares, corresponding to approximately 1.1% of the share capital of the company.
The shares will be purchased on Nasdaq Copenhagen (XCSE) and Multilateral Trading Facilities from time to time, including Cboe DXE (CEUX), Turquoise Europe (TQEX), and Aquis (AQEU).
The shares bought back on each trading day may not exceed 15% of the average daily trading volume over the 20 trading days preceding the date of purchase.
Shares acquired under the share buyback program may not be bought at a price exceeding the higher of (i) the share price of the last independent transaction, and (ii) the highest independent bid on the shares on the trading venue where the transaction is executed. Further, shares may not be bought at a price deviating by more than 10% from the official price quoted on Nasdaq Copenhagen at the time of acquisition for the company’s B-shares.
In accordance with the Safe Harbor Regulations, Ambu will as a minimum for every seventh trading day issue an announcement in respect of transactions made under the share buyback program.
Company announcement no. 7 2025/26
Contacts
- Anders Hjort, Head of Investor Relations, +45 2892 8881, anhj@ambu.com
- Tine Bjørn Schmidt, Director of Corporate Communications, +45 2264 0697, tisc@ambu.com
About Ambu A/S
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.